Citations (35)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (7)
Sean Keane, Pierce Geoghegan, Pedro Povoa, Saad Nseir, Alejandro Rodriguez & Ignacio Martin-Loeches. (2018) Systematic review on the first line treatment of amphotericin B in critically ill adults with candidemia or invasive candidiasis. Expert Review of Anti-infective Therapy 16:11, pages 839-847.
Read now
Read now
Enrico Tagliaferri & Francesco Menichetti. (2015) Treatment of invasive candidiasis: between guidelines and daily clinical practice. Expert Review of Anti-infective Therapy 13:6, pages 685-689.
Read now
Read now
Pola de la Torre & Annette C Reboli. (2014) Micafungin: An Evidence-Based Review of its Place in Therapy. Core Evidence 9, pages 27-39.
Read now
Read now
Oliver A Cornely, Peter G Pappas, Jo-Anne H Young, Philip Maddison & Andrew J Ullmann. (2011) Accumulated safety data of micafungin in therapy and prophylaxis in fungal diseases. Expert Opinion on Drug Safety 10:2, pages 171-183.
Read now
Read now
Patrick Chu & Shalal Sadullah. (2009) The current role of amphotericin B lipid complex in managing systemic fungal infections. Current Medical Research and Opinion 25:12, pages 3011-3020.
Read now
Read now
M. K. Sidhu, A. K. van Engen, J. Kleintjens, O. Schoeman & M. Palazzo. (2009) Cost-effectiveness analysis of micafungin versus caspofungin for treatment of systemic Candida infections in the UK. Current Medical Research and Opinion 25:8, pages 2049-2059.
Read now
Read now
. (2009) Supplement: Trends in invasive Candida infections and their treatment: focus on echinocandins. Current Medical Research and Opinion 25:7, pages 1729-1762.
Read now
Read now
Articles from other publishers (28)
Malini R. Capoor & Abhijit M. Bal. 2022. Comprehensive Pharmacology. Comprehensive Pharmacology
363
371
.
Martyna Mroczyńska & Anna Brillowska-Dąbrowska. (2020) Review on Current Status of Echinocandins Use. Antibiotics 9:5, pages 227.
Crossref
Crossref
Chin Fen Neoh, Esin Senol, Ates Kara, Ener Cagri Dinleyici, Stuart J. Turner & David C. M. Kong. (2018) Economic evaluation of micafungin versus liposomal amphotericin B (LAmB) for treating patients with candidaemia and invasive candidiasis (IC) in Turkey. European Journal of Clinical Microbiology & Infectious Diseases 37:9, pages 1777-1784.
Crossref
Crossref
C. F. Neoh, E. Senol, A. Kara, E. C. Dinleyici, S. J. Turner & D. C. M. Kong. (2017) Pharmacoeconomic evaluation of micafungin versus caspofungin as definitive therapy for candidaemia and invasive candidiasis (IC) in Turkey. European Journal of Clinical Microbiology & Infectious Diseases 37:3, pages 537-544.
Crossref
Crossref
Akash Patil & Soumyajit Majumdar. (2017) Echinocandins in antifungal pharmacotherapy. Journal of Pharmacy and Pharmacology 69:12, pages 1635-1660.
Crossref
Crossref
Chin Fen Neoh, Esin Senol, Ates Kara, Ener Cagri Dinleyici, Stuart J. Turner & David C. M. Kong. (2017) Cost-effectiveness analysis of anidulafungin vs fluconazole for the treatment of invasive candidiasis (IC) in Turkey. Mycoses 60:11, pages 714-722.
Crossref
Crossref
M. Ruhnke. (2014) Antifungal stewardship in invasive Candida infections. Clinical Microbiology and Infection 20, pages 11-18.
Crossref
Crossref
Chin Fen Neoh, Monica Slavin, Sharon C.-A. Chen, Kay Stewart & David C.M. Kong. (2014) Echinocandins in the treatment of candidaemia and invasive candidiasis: clinical and economic perspectives. International Journal of Antimicrobial Agents 43:3, pages 207-214.
Crossref
Crossref
Hongbo Yang, Paresh Chaudhari, Zheng-Yi Zhou, Eric Q. Wu, Chad Patel & David L. Horn. (2014) Budget Impact Analysis of Liposomal Amphotericin B and Amphotericin B Lipid Complex in the Treatment of Invasive Fungal Infections in the United States. Applied Health Economics and Health Policy 12:1, pages 85-93.
Crossref
Crossref
L. Drgona, A. Khachatryan, J. Stephens, C. Charbonneau, M. Kantecki, S. Haider & R. Barnes. (2013) Clinical and economic burden of invasive fungal diseases in Europe: focus on pre-emptive and empirical treatment of Aspergillus and Candida species. European Journal of Clinical Microbiology & Infectious Diseases 33:1, pages 7-21.
Crossref
Crossref
Chin Fen Neoh, Danny Liew, Monica A. Slavin, Debbie Marriott, Sharon C.-A. Chen, Orla Morrissey, Kay Stewart & David C. M. Kong. (2013) Economic evaluation of micafungin vs. Liposomal Amphotericin B (LAmB) for the treatment of candidaemia and Invasive Candidiasis (IC). Mycoses 56:5, pages 532-542.
Crossref
Crossref
S. Grau, M. Salavert, J. Carlos Pozo Laderas, M. García Vargas, J.A. Barrueta & N. Mir. (2013) Cost-effectiveness of anidulafungin in confirmed candidaemia and other invasive Candida infections in Spain. Journal de Mycologie Médicale 23:3, pages 155-163.
Crossref
Crossref
C. F. Neoh, D. Liew, M. A Slavin, D. Marriott, S. C.-A. Chen, O. Morrissey, K. Stewart & D. C. M. Kong. (2013) Economic evaluation of micafungin versus caspofungin for the treatment of candidaemia and invasive candidiasis. Internal Medicine Journal 43:6, pages 668-677.
Crossref
Crossref
Elizabeth Dodds Ashley, Richard Drew, Melissa Johnson, Robert Danna, Dominika Dabrowski, Valery Walker, Manishi Prasad, Barbara Alexander, George Papadopoulos & John Perfect. (2012) Cost of Invasive Fungal Infections in the Era of New Diagnostics and Expanded Treatment Options. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 32:10, pages 890-901.
Crossref
Crossref
Elizabeth Dodds Ashley, Richard Drew, Melissa Johnson, Robert Danna, Dominika Dabrowski, Valery Walker, Manishi Prasad, Barbara Alexander, George Papadopoulos & John Perfect. (2012) Cost of Invasive Fungal Infections in the Era of New Diagnostics and Expanded Treatment Options. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, pages n/a-n/a.
Crossref
Crossref
M. García-Vargas, M.A. Casado, N. Mir & J.A. Barrueta. (2012) Análisis de costes de tres candinas en el tratamiento de la candidiasis invasora en pacientes adultos no neutropénicos en España. Farmacia Hospitalaria 36:4, pages 207-215.
Crossref
Crossref
Matteo Bassetti, Franco Aversa, Filippo Ballerini, Fabio Benedetti, Alessandro Busca, Nicola Cascavilla, Ercole Concia, Andrea Tendas, Francesco Di Raimondo, Patrizio Mazza, Anna Maria Nosari & Giuseppe Rossi. (2011) Amphotericin B Lipid Complex in the Management of Invasive Fungal Infections in Immunocompromised Patients. Clinical Drug Investigation 31:11, pages 745-758.
Crossref
Crossref
Annette C. Reboli, Coleman Rotstein, Daniel H. Kett, Michael Maschio, Shannon Cartier, Richard Chambers & Miriam Tarallo. (2011) Resource Utilization and Cost of Treatment with Anidulafungin or Fluconazole for Candidaemia and Other Forms of Invasive Candidiasis. PharmacoEconomics 29:8, pages 705-717.
Crossref
Crossref
Elizabeth Dodds Ashley. (2011) Pharmacoeconomics of antifungal therapy: current considerations. Current Opinion in Infectious Diseases 24, pages S30-S40.
Crossref
Crossref
C. F. Neoh, D. Liew, M. Slavin, D. Marriott, S. C.- A. Chen, O. Morrissey, K. Stewart & D. C. M. Kong. (2011) Cost-effectiveness analysis of anidulafungin versus fluconazole for the treatment of invasive candidiasis. Journal of Antimicrobial Chemotherapy 66:8, pages 1906-1915.
Crossref
Crossref
Shannon L. Holt & Richard H. Drew. (2011) Echinocandins: Addressing outstanding questions surrounding treatment of invasive fungal infections. American Journal of Health-System Pharmacy 68:13, pages 1207-1220.
Crossref
Crossref
G Kofla & M Ruhnke. (2011) Pharmacology and metabolism of anidulafungin, caspofungin and micafungin in the treatment of invasive candidosis - review of the literature. European Journal of Medical Research 16:4, pages 159.
Crossref
Crossref
Stefan Felder, Kristin Grabe & Thomas Mayrhofer. (2013) Micafungin im Vergleich zu Caspofungin bei der Behandlung von invasiven Candida-Infektionen: Eine Kosteneffektivitätsanalyse für DeutschlandMicafungin versus caspofungin for the treatment of systemic Candida infections: A cost-effectiveness analysis for Germany. PharmacoEconomics German Research Articles 8:2, pages 71-83.
Crossref
Crossref
Dustin T. Wilson, Richard H. Drew & John R. Perfect. (2009) Antifungal Therapy for Invasive Fungal Diseases in Allogeneic Stem Cell Transplant Recipients: An Update. Mycopathologia 168:6, pages 313-327.
Crossref
Crossref
Natalie J. Carter & Gillian M. Keating. (2009) Micafungin. Pediatric Drugs 11:4, pages 271-291.
Crossref
Crossref
Sarah M. Wieczorkiewicz, Jacqueline Jourjy & Larry Danziger. (2009) An update on the pharmacoeconomics of antifungal pharmacotherapy. Current Fungal Infection Reports 3:2, pages 103-110.
Crossref
Crossref
Hyun Soon Sohn, Tae-Jin Lee, Jinhyun Kim & Donghwan Kim. (2009) Cost-effectiveness analysis of micafungin versus fluconazole for prophylaxis of invasive fungal infections in patients undergoing hematopoietic stem cell transplantation in Korea. Clinical Therapeutics 31:5, pages 1105-1115.
Crossref
Crossref
Marit D. Moen, Katherine A. Lyseng-Williamson & Lesley J. Scott. (2009) Liposomal Amphotericin B. Drugs 69:3, pages 361-392.
Crossref
Crossref